Agentic AI company Owkin just signed a three-year licensing deal with AstraZeneca (AZN) to build specialized biopharma AI agents using its K Pro platform. This expands an existing collaboration that was already focused on drug discovery and development.
The agreement lets Owkin create end-to-end AI agents that will operate inside AstraZeneca's own infrastructure and decision-making workflows. The tools are meant to support competitive intelligence and give teams faster access to data-driven insights, cutting down on manual analysis.
Owkin describes K Pro as an "AI Scientist" platform built for pharmaceutical research and strategic decision-making. It combines multimodal data with agentic AI tools to help researchers interpret complex biological information and boost productivity across the pharmaceutical value chain. Under the deal, AstraZeneca's teams will use these agents within established governance, security, and compliance standards.
Thomas Clozel, CEO and co-founder of Owkin, said the pharmaceutical industry is moving toward agentic AI systems that can handle complex business and research decisions. "At Owkin, we believe the future of the pharmaceutical industry is agentic," Clozel said. He added that the company's multimodal data network and AI infrastructure allow it to develop agents that can help pharmaceutical executives make faster decisions.
This latest agreement builds on earlier work between the two companies involving an AI gBRCA pre-screening solution for breast cancer patients. Owkin said ongoing findings from that collaboration were presented at ESMO, where the BRCAura RUO solution demonstrated the ability to rule out roughly 40% of patients unlikely to carry gBRCA mutations while maintaining 93% sensitivity. That diagnostic work is now continuing under Waiv, a spinout from Owkin's diagnostics division. Owkin itself is focusing on what it calls Biological Artificial Superintelligence aimed at solving complex biological challenges.
AZN Price Action: AstraZeneca shares were up 0.59% at $185.62 at the time of publication on Wednesday. Over the past month, AZN has declined about 8.3% versus a 9.2% rise in the S&P 500 and is up roughly 0% year-to-date compared to the index's 7.9% gain.
